Societe Generale’s Teva Pharmaceuticals TEVA Stock Holding History

Societe Generale’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$439K	Buy	+189,000	New	+$10.1M	﹤0.01%	1767

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Societe Generale's TEVA Position: Q2 2016 in Review

Societe Generale opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2016: 295,269 shares worth $14.8M. The stake represents 0.11% of the portfolio and ranks #152 among its holdings.

812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Societe Generale held 295,269 shares of Teva Pharmaceuticals worth $14.8M as of Q2 2016.
Teva Pharmaceuticals was a new Societe Generale position in Q2 2016.
Teva Pharmaceuticals made up 0.11% of Societe Generale's portfolio in Q2 2016, its #152 holding.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.